在加入药明康德之前，Hausheer博士在多家生物制药公司担任首席执行官和首席医学官，他曾是BioNumerik Pharmaceuticals公司的创始人兼董事长。他还是摩根大通（JP an Chase）、约翰霍普金大学惠特克研究所（Whittaker Institute at Johns Hopkins）、美国国家癌症研究所（National Cancer Institute, NCI）等多家组织机构的商业咨询委员会成员。在他职业生涯早期，Hausheer博士曾在NCI的实验治疗部、决策网络小组和机构审委员会任职，广泛参与了众多国家级和国际级的临床I-III期试验项目，项目内容涉及肺癌、乳腺癌、卵巢癌以及其他恶性肿瘤的创新疗法。
Wu AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer
SHANGHAI and AUSTIN, Texas, April 8, 2019 -- Wu AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.
In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to Wu Clinical operations in the United States, China and other territories. In addition, he will play a key role in ing and maintaining strong connections between our customers and Wu’s business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.
Dr. Hausheer brings more than 30 years&39; experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.
“We’re very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer,” said Mr. Edward Hu, Co-CEO of Wu AppTec. “Dr. Hausheer’s rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen Wu’s clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world.”
Prior to joining Wu, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP an Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.
Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.
About Wu AppTec
Wu AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, Wu AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, Wu platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill Wu&39;s dream that &34;every drug can be made and every disease can be treated.&34; Please visit: http://wuxiapptec.com
使用《赢家江恩软件》官方看图分析该股>>
刘积惠
药明康德任命Frederick H. Hausheer博士为首席医学官
▎【药明康德(603259)、股吧】/报道
药明康德任命Frederick H. Hausheer博士为首席医学官
中国上海，美国德克萨斯州奥斯汀，2019年4月8日——药明康德今天宣布Frederick H. Hausheer博士已正式加入公司，担任首席医学官（Chief Medical Officer）。
Hausheer博士将主导药明康德临床开发服务业务在美国、中国以及全球各地的医疗、科学及运营管理工作。此外，他将为公司提供医学和临床开发方面的战略指导，以加强各业务部门与合作伙伴间的紧密联系，促进从临床前转化研究与开发，到首次人体临床试验（FIH），再到为客户制定I-IV期临床开发计划的一站式服务平台的无缝衔接。
Hausheer博士在全球肿瘤临床药物开发、转化科学和医学方面拥有超过30年的商业及学术经验。他在转化研究/新药临床试验申请、临床试验设计、商业临床开发等领域经验丰富，曾广泛参与从新药临床试验申请前期，到I-III期临床试验的监管沟通工作，项目范围涉及欧、美、中、日等多个国家和地区。
“我们非常欢迎Hausheer博士加盟并担任首席医学官，”药明康德联席首席执行官胡正国先生表示，“Hausheer博士在全球肿瘤药物开发、临床研究及医疗领域等方面有着丰富的经验。相他的加入，将进一步增强公司在全球的临床服务能力和规模，更好地赋能全球客户，助推更多新药、好药早日问世，造福广大病患。”
在加入药明康德之前，Hausheer博士在多家生物制药公司担任首席执行官和首席医学官，他曾是BioNumerik Pharmaceuticals公司的创始人兼董事长。他还是摩根大通（JP an Chase）、约翰霍普金大学惠特克研究所（Whittaker Institute at Johns Hopkins）、美国国家癌症研究所（National Cancer Institute, NCI）等多家组织机构的商业咨询委员会成员。在他职业生涯早期，Hausheer博士曾在NCI的实验治疗部、决策网络小组和机构审委员会任职，广泛参与了众多国家级和国际级的临床I-III期试验项目，项目内容涉及肺癌、乳腺癌、卵巢癌以及其他恶性肿瘤的创新疗法。
Hausheer博士在密苏里大学医学院获得医学博士学位，毕业后在约翰霍普金斯肿瘤中心任职，专注于创新实验疗法和药理学。目前Hausheer博士还在密苏里大学以及约翰霍普金斯肿瘤中心内科肿瘤科担任兼职教授。此外，他还是400多项美国及国际专利的发明者或共同发明人。
关于药明康德
药明康德（股票代码：603259/2359.HK）是国际领先的开放式能力与技术平台公司，为全球制药及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等，正承载着来自全球30多个国家的3500多家创新合作伙伴的数千个研发创新项目，致力于将最新和最好的医药和健康产品带给全球病患，实现“让天下没有难做的药，难治的病”的梦想。更多息，请访问公司网站：wuxiapptec.com
Wu AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer
SHANGHAI and AUSTIN, Texas, April 8, 2019 -- Wu AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.
In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to Wu Clinical operations in the United States, China and other territories. In addition, he will play a key role in ing and maintaining strong connections between our customers and Wu’s business units by providing inputs on medical and clinical development strategies aimed at seamless integration from preclinical translational research and development into first-in-human studies, as well as for Phase I-IV clinical development plans for our customers.
Dr. Hausheer brings more than 30 years&39; experience in global oncology clinical drug development and translational science and medicine in commercial and academic settings. He has extensive experience in translational/IND programs, clinical trial design, commercial clinical development, and involvement in regulatory interactions for novel agents spanning from pre-IND and Phase I-III development in the United States, China, Europe, Japan and other territories.
“We’re very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer,” said Mr. Edward Hu, Co-CEO of Wu AppTec. “Dr. Hausheer’s rich experience in global oncology clinical drug development and translational science and medicine makes him ideally suited to taking this role. We are confident in his leadership to strengthen Wu’s clinical development capabilities and capacity globally, and enable more customers to develop better medicine faster to benefit patients around the world.”
Prior to joining Wu, Dr. Hausheer held CEO and CMO positions with several Biopharma companies, and was the Founder and Chairman of BioNumerik Pharmaceuticals. He has also served as a business advisory board member to JP an Chase, the Whittaker Institute at Johns Hopkins, and the National Cancer Institute. Early in his career he served on the National Cancer Institute (NCI) Experimental Therapeutics Section, the NCI Decision Network Panel, and the NCI Institutional Review Board, followed by extensive involvement in national and international Phase I-III clinical trials involving novel treatments for lung, breast, ovarian and other malignancies.
Dr. Hausheer obtained his MD at the University of Missouri, School of Medicine and then became a faculty member at the Johns Hopkins Oncology Center, where he focused on the development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is an inventor/co-inventor on more than 400 issued United States and international patents.
About Wu AppTec
Wu AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, Wu AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, Wu platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill Wu&39;s dream that &34;every drug can be made and every disease can be treated.&34; Please visit: http://wuxiapptec.com
分享：
相关帖子